Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors

Bonnie J. Takasugi, Aurelia B. Robertone, Sydney E. Salmon, Stephen E. Jones, David S Alberts

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This Phase I-II trial evaluated vinzolidine (VZL), a semisynthetic vinblastine derivative administered on a five-day oral schedule every 21 days, with 60% of the total dose on day 1 followed by 10% of the total on each of the following four days. Forty-four patients with advanced malignancies were entered in this study and 34 were evaluable for response. Three patients responded, with complete remissions in patients with adenocarcinoma of the lung (39+ weeks) and adenocarcinoma of the pancreas (20 + weeks) and a minor response in a patient with metastatic carcinoid (6 weeks). Myelosuppression was the dose-limiting toxicity, and was remarkable for its unpredictability among patients and even in the same patient receiving a constant dose of vinzolidine. There was one drug related death associated with myelosuppression. This study was closed because of the erratic myelotoxicity of oral vinzolidine. However, the activity observed with vinzolidine merits future trials, using a parenteral formulation which may have more predictable toxicity.

Original languageEnglish (US)
Pages (from-to)387-390
Number of pages4
JournalInvestigational New Drugs
Volume2
Issue number4
DOIs
StatePublished - Dec 1984

Fingerprint

Vinca Alkaloids
Appointments and Schedules
Neoplasms
Vinblastine
Carcinoid Tumor
vinzolidine
Pancreas
Adenocarcinoma
Pharmaceutical Preparations

Keywords

  • five-day schedule
  • vinzolidine

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors. / Takasugi, Bonnie J.; Robertone, Aurelia B.; Salmon, Sydney E.; Jones, Stephen E.; Alberts, David S.

In: Investigational New Drugs, Vol. 2, No. 4, 12.1984, p. 387-390.

Research output: Contribution to journalArticle

Takasugi, Bonnie J. ; Robertone, Aurelia B. ; Salmon, Sydney E. ; Jones, Stephen E. ; Alberts, David S. / Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors. In: Investigational New Drugs. 1984 ; Vol. 2, No. 4. pp. 387-390.
@article{d8df6e6b79c24658a3f5fe8281830ca6,
title = "Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors",
abstract = "This Phase I-II trial evaluated vinzolidine (VZL), a semisynthetic vinblastine derivative administered on a five-day oral schedule every 21 days, with 60{\%} of the total dose on day 1 followed by 10{\%} of the total on each of the following four days. Forty-four patients with advanced malignancies were entered in this study and 34 were evaluable for response. Three patients responded, with complete remissions in patients with adenocarcinoma of the lung (39+ weeks) and adenocarcinoma of the pancreas (20 + weeks) and a minor response in a patient with metastatic carcinoid (6 weeks). Myelosuppression was the dose-limiting toxicity, and was remarkable for its unpredictability among patients and even in the same patient receiving a constant dose of vinzolidine. There was one drug related death associated with myelosuppression. This study was closed because of the erratic myelotoxicity of oral vinzolidine. However, the activity observed with vinzolidine merits future trials, using a parenteral formulation which may have more predictable toxicity.",
keywords = "five-day schedule, vinzolidine",
author = "Takasugi, {Bonnie J.} and Robertone, {Aurelia B.} and Salmon, {Sydney E.} and Jones, {Stephen E.} and Alberts, {David S}",
year = "1984",
month = "12",
doi = "10.1007/BF00171590",
language = "English (US)",
volume = "2",
pages = "387--390",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors

AU - Takasugi, Bonnie J.

AU - Robertone, Aurelia B.

AU - Salmon, Sydney E.

AU - Jones, Stephen E.

AU - Alberts, David S

PY - 1984/12

Y1 - 1984/12

N2 - This Phase I-II trial evaluated vinzolidine (VZL), a semisynthetic vinblastine derivative administered on a five-day oral schedule every 21 days, with 60% of the total dose on day 1 followed by 10% of the total on each of the following four days. Forty-four patients with advanced malignancies were entered in this study and 34 were evaluable for response. Three patients responded, with complete remissions in patients with adenocarcinoma of the lung (39+ weeks) and adenocarcinoma of the pancreas (20 + weeks) and a minor response in a patient with metastatic carcinoid (6 weeks). Myelosuppression was the dose-limiting toxicity, and was remarkable for its unpredictability among patients and even in the same patient receiving a constant dose of vinzolidine. There was one drug related death associated with myelosuppression. This study was closed because of the erratic myelotoxicity of oral vinzolidine. However, the activity observed with vinzolidine merits future trials, using a parenteral formulation which may have more predictable toxicity.

AB - This Phase I-II trial evaluated vinzolidine (VZL), a semisynthetic vinblastine derivative administered on a five-day oral schedule every 21 days, with 60% of the total dose on day 1 followed by 10% of the total on each of the following four days. Forty-four patients with advanced malignancies were entered in this study and 34 were evaluable for response. Three patients responded, with complete remissions in patients with adenocarcinoma of the lung (39+ weeks) and adenocarcinoma of the pancreas (20 + weeks) and a minor response in a patient with metastatic carcinoid (6 weeks). Myelosuppression was the dose-limiting toxicity, and was remarkable for its unpredictability among patients and even in the same patient receiving a constant dose of vinzolidine. There was one drug related death associated with myelosuppression. This study was closed because of the erratic myelotoxicity of oral vinzolidine. However, the activity observed with vinzolidine merits future trials, using a parenteral formulation which may have more predictable toxicity.

KW - five-day schedule

KW - vinzolidine

UR - http://www.scopus.com/inward/record.url?scp=0021677269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021677269&partnerID=8YFLogxK

U2 - 10.1007/BF00171590

DO - 10.1007/BF00171590

M3 - Article

C2 - 6096287

AN - SCOPUS:0021677269

VL - 2

SP - 387

EP - 390

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -